Additional information:
Mahanine is a carbazole alkaloid with various biological properties.PMID:23489613 Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits antileishmanial activity and can be used for Leishmania infection treatment research.|Product information|CAS Number: 28360-49-8|Molecular Weight: 347.45|Formula: C23H25NO2|Chemical Name: (3R)-3,5-dimethyl-3-(4-methylpent-3-en-1-yl)-3H,11H-pyrano[3,2-a]carbazol-9-ol|Smiles: CC(C)=CCC[C@]1(C)C=CC2C3NC4=CC(O)=CC=C4C=3C=C(C)C=2O1|InChiKey: DWMBXHWBPZZCTN-HSZRJFAPSA-N|InChi: InChI=1S/C23H25NO2/c1-14(2)6-5-10-23(4)11-9-18-21-19(12-15(3)22(18)26-23)17-8-7-16(25)13-20(17)24-21/h6-9,11-13,24-25H,5,10H2,1-4H3/t23-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Mahanine (0-50 µM; 24 or 48 hours) induces a dose-dependent decrease in cell viability of AG83 promastigotes after 24 hr and 48 hr; the IC50 values were 16.7±1.7 µM and 11.5±0.8 µM respectively. In a drug resistant GE1 strain, Mahanine treatment exhibits dose-dependent cell death in 24 and 48 hr treatment with IC50 values 40.3±2.2 µM and 29.1±1.3 µM respectively. Mahanine (5.0 and 10 µM; 24 hours) exhibits increased accumulation of cells at G2/M phase being 39.0±1.90% and 41.0±2.10% respectively compared to untreated promastigotes (35.3 ± 2.60%) in AG83 promastigote . Mahanine (25 µM; 24 hours) exhibitssignificantly increased intracellular ROS level within 20 min (MFI being 889 ± 26) which reached to 1288 ± 56 after one hour compared to the basal level (604 ± 34) in untreated promastigote. H2DCFDA positivity was measured by FACS.|In Vivo:|Mahanine (oral gavage; 20 mg/kg/40 mg/kg; b.w/day; 5 days) results in 89.1±4.1% reductions in parasite burden at 20 mg/kg, and leads to 96.2±0.3% reductions in parasite burden at 40 mg/kg in a well-established acute model to control Leishmania infection.|Products are for research use only. Not for human use.|